TNF inhibitor
3 years 1 month ago
Study on enthesitis response to biologic Rx
⭐️TNFI caused a 2❎ 🔽mean ActiveMASEI score compared to secukinumab
⭐️ 🔽PASI and DLQI score more in TNFI than Secukinumab
🔰Superiority of TNFi versus secukinumab in regards to active enthesitis
Abst#1356 #ACR21 @Rheumnow https://t.co/wdzMYmn8AJ
3 years 1 month ago
Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi showed a more marked decrease in US enthesitis. Abstr#1356 #ACR21 @RheumNow https://t.co/XXgYMgkMyP
3 years 1 month ago
Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM
3 years 1 month ago
In this study,
⭕AS pts w/>=2 #comorbidities were associated w/ poorer outcome measures after 2 yrs of ffup vs. pts w/ no comorbids
⭕Pts w/ >=2 comorbids were likely to dc 1st anti-TNF
Address comorbidities, ⬆ chances of better outcomes & QoL
@RheumNow #ACR21 abs1309 https://t.co/sTnjaC1a1l
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest…
3 years 1 month ago
As old saying but updated goes: Wise man/woman/prefer not to answer says IF you STOP drugs they usually STOP working. True with TNFi in most diseases (RA, axSpA, etc). Also tue with #plaquenil in large #SLE study #ACR21 abst#0959 https://t.co/O6Ejg5sjjK
A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axial spondyloarthritis (ax-Spa), whether they are diagnosed with…
Poster Hall